Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.
Can anything threaten Novo and Lilly’s obesity market dominance?
Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.
